Dark

ABSI
Absci Corporation Common Stock
stock NASDAQ

Market Open

Jul 28, 2026 1:12:19 PM EDT

7.21USD-4.630%(-0.35)1,683,999

7.20Bid 7.21Ask 0.01Spread

Pre-market

Jul 27, 2026 9:28:30 AM EDT

7.78USD+2.910%(+0.22)0

After-hours

Jul 27, 2026 4:06:30 PM EDT

7.62USD+0.794%(+0.06)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 7, 2022

02:50PM EST Mid-Afternoon Market Update: Dow Gains Over 100 Points; Aehr Test Systems Shares Slide Benzinga

01:09PM EST Mid-Day Market Update: Nasdaq Tumbles 150 Points; Marin Software Shares Jump Benzinga

01:07PM EST Mid-Morning Market Update: Markets Mixed; US Economy Adds Just 199,000 Jobs In December Benzinga

01:01PM EST Absci Announces Research Collaboration with Merck; Absci Eligible to Receive up to $610M in Upfront Fees and Milestone Payments Plus Royalties Benzinga

09:58AM EST Shares of Absci Corporation (ABSI) are surging over 40% on Friday morning after the company announced a collaboration deal with Merck that could award the company up to $610 million in fees and payments. RTTNews

05:00AM EST Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced that it has entered into a research collaboration with Merck (known as MSD outside the United States and Canada), using Abscis AI-powered Integrated Drug Creation Platform. GlobeNewswire Inc

Jan 5, 2022

04:05PM EST Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the company will be participating virtually in the upcoming 40th Annual J.P. Morgan Healthcare Conference. GlobeNewswire Inc

11:07AM EST Stocks That Hit 52-Week Lows On Wednesday Benzinga

Dec 30, 2021

08:05AM EST Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the company will be participating in the H.C. Wainwright BIOCONNECT Virtual Conference. GlobeNewswire Inc

Dec 29, 2021

06:51PM EST Investigation Alert: Did You Lose Money on Your Stock? Johnson Fistel, LLP PR Newswire

Nov 18, 2021

04:21PM EST Pomerantz LLP is investigating claims on behalf of investors of Absci Corporation (Absci or the Company) (NASDAQ: ABSI). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

Nov 10, 2021

12:16PM EST Where Absci Stands With Analysts Benzinga

10:03AM EST Benzinga's Top Ratings Upgrades, Downgrades For November 10, 2021 Benzinga

06:20AM EST B of A Securities Downgrades Absci to Underperform, Lowers Price Target to $10 Benzinga

Nov 9, 2021

01:08PM EST Absci Earlier Reported Q3 EPS $(0.33) Misses $(0.18) Estimate, Sales $1.54M Miss $2.01M Estimate Benzinga

11:25AM EST Earnings Scheduled For November 9, 2021 Benzinga

07:00AM EST Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today reported financial and operating results for the quarter ended September 30, 2021. GlobeNewswire Inc

Oct 20, 2021

04:05PM EDT Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the opening of its new campus located in Vancouver, Washington, a few miles east of the downtown location that housed the company for the last four years. GlobeNewswire Inc

Oct 14, 2021

04:05PM EDT Absci to Report Third Quarter Financial Results on November 9, 2021 GlobeNewswire Inc

Oct 12, 2021

08:13AM EDT The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology Benzinga

Oct 6, 2021

07:28AM EDT EQRx, Absci Ink Protein-Based Therapeutics Development Pact Benzinga

06:05AM EDT EQRx And Absci Announce Partnership To Discover And Develop Next-Generation Protein-Based Drugs Benzinga

06:00AM EDT EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, and Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced a discovery collaboration. GlobeNewswire Inc

Sep 23, 2021

07:57AM EDT The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data Benzinga

Sep 22, 2021

07:45AM EDT The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs Benzinga

Sep 21, 2021

08:20AM EDT The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data Benzinga

Sep 17, 2021

07:36AM EDT The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold Benzinga

Sep 13, 2021

04:05PM EDT Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning and synthetic biology to expand the therapeutic potential of proteins, today announced the company will be participating virtually in the upcoming BofA Securities 2021 Tech Solutions for Drug Discovery Conference. GlobeNewswire Inc

Sep 10, 2021

08:00AM EDT The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test Benzinga

Sep 9, 2021

08:17AM EDT The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization Benzinga

Sep 7, 2021

08:47AM EDT Absci Q2 Sales $700K, Up From $600K YoY Benzinga

08:30AM EDT Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning and synthetic biology to expand the therapeutic potential of proteins, today reported financial and operating results for the quarter ended June 30, 2021. GlobeNewswire Inc

Aug 31, 2021

08:15AM EDT The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical Benzinga

Aug 19, 2021

10:57AM EDT The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck Benzinga

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 17, 2021

08:28AM EDT The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business Benzinga

Aug 16, 2021

10:34AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 16, 2021 Benzinga

08:19AM EDT Stifel Initiates Coverage On Absci with Hold Rating, Announces Price Target of $28 Benzinga

07:44AM EDT B of A Securities Initiates Coverage On Absci with Neutral Rating, Announces Price Target of $26 Benzinga

07:24AM EDT Cowen & Co. Initiates Coverage On Absci with Market Perform Rating Benzinga

05:07AM EDT Credit Suisse Initiates Coverage On Absci with Outperform Rating, Announces Price Target of $40 Benzinga

Aug 15, 2021

12:16PM EDT The Week Ahead In Biotech: Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow Benzinga

11:06AM EDT The Week Ahead In Biotech (Aug. 15-21): Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow Benzinga

Aug 5, 2021

08:08AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO Benzinga

Aug 4, 2021

07:52AM EDT The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings Benzinga

Aug 3, 2021

07:55AM EDT The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business Benzinga

Jul 30, 2021

07:54AM EDT The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs Benzinga

Jul 28, 2021

10:14AM EDT The IPO Recap Party Is Everything But Over Benzinga

Jul 27, 2021

11:13AM EDT The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts Benzinga

Jul 26, 2021

04:00PM EDT Absci Announces Closing of Public Offering and Full Exercise of GlobeNewswire Inc

Jul 22, 2021

12:15PM EDT Absci Corporation Shares Open For Trade At $21; IPO Priced At $16/Share Benzinga

10:45AM EDT Absci Corporation Shares Indicating $25 Benzinga

09:43AM EDT Absci Corporation Shares Will Open For Quote At 10:10 a.m. EDT, Expected To Open For Trade After 10:20 a.m. EDT; IPO Priced At $16/Share Benzinga

.dark-mode .C2qXzc{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .C2qXzc{ color: #333333; background-color: white; border: 2px solid #333333; }ABSIAbsci Corporation Common Stockstock NASDAQ

ABSI
Absci Corporation Common Stock
stock NASDAQ